ArticleDiabetologia2005
A prospective study of lipoprotein(a) and risk of coronary heart disease among women with type 2 diabetes.
Article in Diabetologia, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Serum/plasma biomarkers and the progression of cardiometabolic multimorbidity: a systematic review and meta-analysis.Frontiers in public health · 2023Pooled it
- The relationship between Lp(a) and CVD outcomes: a systematic review.Lipids in health and disease · 2016Pooled it
- Lipoprotein(a), Cardiovascular Events and Sex Differences: A Single Cardiological Unit Experience.Journal of clinical medicine · 2023Article
- Correlations Between Coronary Artery Disease, Coronary Artery Calcium Score, and Lipoprotein(a) Level in Korea.Therapeutics and clinical risk management · 2022Article
- Metabolic syndrome, lipoprotein(a) and subclinical atherosclerosis in Mexican populationArchivos de cardiologia de Mexico · 2021Article
- Levels of Apolipoprotein A1, B100 and Lipoprotein (a) in Controlled and Uncontrolled Diabetic Patients and in Non-Diabetic Healthy People.Journal of clinical and diagnostic research : JCDR · 2017Article
- Elevated lipoprotein(a) levels predict cardiovascular disease in type 2 diabetes mellitus: a 10-year prospective cohort study.The Korean journal of internal medicine · 2016Observational
- Lipoprotein(a) and cardiovascular disease in diabetic patients.Clinical lipidology · 2012Article
- Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes.European heart journal · 2012Article
- Lipoprotein(a) is strongly associated with coronary artery calcification in type-2 diabetic women.International journal of cardiology · 2011Article
- Lipoprotein(a): an independent risk factor for ischemic heart disease that is dependent on triglycerides in subjects with type 2 diabetes mellitus.Lipids in health and disease · 2007Article
- Circulating leptin levels are not associated with cardiovascular morbidity and mortality in women with diabetes: a prospective cohort study.Diabetologia · 2007Article
- Cardiovascular risk assessment in type 2 diabetes mellitus.Current diabetes reports · 2006Review
- A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease.Proceedings of the National Academy of Sciences of the United States of America · 2006Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
aimsWe examined the association between lipoprotein (Lp)(a) and CHD among women with type 2 diabetes.
methodsOf 32,826 women from the Nurses' Health Study who provided blood at baseline, we followed 921 who had a confirmed diagnosis of type 2 diabetes.
resultsDuring 10 years of follow-up (6,835 person-years), we documented 122 incident cases of CHD. After adjustment for age, smoking, BMI, glycosylated HbA(1)c, triglycerides (TGs), high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and other cardiovascular risk factors, the relative risk (RR) comparing extreme quintiles of Lp(a) was 1.95 (95% CI 1.07-3.56). The association was not appreciably altered after further adjustment for apolipoprotein B(100) or several inflammatory biomarkers. Increasing levels of Lp(a) were associated with lower levels of TGs. The probability of developing CHD over 10 years was higher among diabetic women with substantially higher levels of both Lp(a) (>1.07 micromol/l) and TGs (>2.26 mmol/l) than among diabetic women with lower levels (22 vs 10%, p log-rank test=0.049). Diabetic women with a higher level of only Lp(a) or TGs had a similar (14%) risk. In a multivariate model, diabetic women with higher levels of Lp(a) and TGs had an RR of 2.46 (95% CI 1.21-5.01) for developing CHD, as compared with those with lower levels of both biomarkers (p for interaction=0.413). The RRs for women with a higher level of either Lp(a) (RR=1.22, 95% CI 0.77-1.92) or TGs (RR=1.39, 95% CI 0.78-2.42) were comparable. CONCLUSIONS/
interpretationIncreased levels of Lp(a) were independently associated with risk of CHD among diabetic women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.